FinalDose
Programmable DNA drug destroying all cancers, unlocking 80% of targets
Note: This is a preliminary assessment based on limited publicly available information. We did not have access to LinkedIn profiles or live product screenshots for this analysis. We will update this entry with a more thorough review soon.
Verdict
FinalDose has one of the strongest founding teams in the batch — three Oxford PhDs with genuine domain depth, and a CEO who already raised $15M and shipped a real product at Vivid Dx. The scientific vision is ambitious and potentially transformative, targeting genuinely undruggable cancer targets. However, this is deep pre-clinical biotech with zero visible traction, no published data, and an extraordinary technical claim ('destroying all cancers') that requires years and hundreds of millions of dollars to validate. The gap between the vision and current reality is enormous even by biotech standards. YC is an unusual fit for this stage of drug development — the real test is whether they can generate enough early mechanistic proof to raise serious Series A biotech money, not whether they can hit typical YC growth metrics.
Active Founders
Founder at FinalDose (YC P26). DPhil in Biochemistry from Oxford, where he spent 5 years as a postdoctoral researcher at the MRC Weatherall Institute of Molecular Medicine. Led CRISPR screening projects uncovering new druggable targets in cancer cells and built pipelines reducing hit validation time from months to 7 days. Research focuses on BRCA1-deficient cancers and PARP inhibitor resistance mechanisms.
Cofounder and CTO at FinalDose (YC P26). Oxford PhD in Computational Biology with Wellcome Trust full scholarship. Previously Data Lead at Gutsee Biotech. Developed novel machine learning method to use coevolution biology to identify genetic targets that convey drug resistance in viruses. During SARS-CoV-2 pandemic, led UK biobank analysis of human genetics susceptibility for infections
CEO @ FinalDose (YC P26). Oxford PhD in Oncology. Previous startup (Vivid Dx) solved a multi-decade bottleneck in sepsis diagnostics: low biomass isolation. By overcoming this hurdle, we built the world’s fastest diagnostic system - slashing wait times from 5 days to just 30 minutes. Raised $15M in venture backing.